Home Icon

Loading, Please Wait...

Geron to Provide an Update on the Imetelstat Collaboration with Janssen on September 27, 2018

897 Days ago

MENLO PARK, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will host a conference call to provide an update on the imetelstat collaboration with Janssen Biotech, Inc. (Janssen) on Thursday, September 27th at 8:00 a.m. ET.

Participants may access the conference call live via telephone by dialing domestically +1 (877) 303-9139 or internationally +1 (760) 536-5195. The passcode is 7987354. Participants are advised to dial in at least 10 minutes prior to minimize any delay in joining the call. A live, listen-only webcast will also be available on the Company’s website at www.geron.com/investors/events. If you are unable to listen to the live call, an archived webcast will be available on the Company’s website for 30 days.

About Geron

Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.

CONTACT:

Suzanne Messere
Investor and Media Relations
investor@geron.com
media@geron.com

CG Capital
877-889-1972

We Are Diffrent
Is your business listed correctly on America’s largest city directory network of 1,000 portals? Find your City Portal